Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fresenius Kabi

< Previous 1 2 Next >
FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilars Conexxence® and Bomyntra® (denosumab-bnht)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Announces 13 New Inductees Into the National Blood Donation Hall of Fame
From Fresenius Kabi
Via Business Wire
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Conexxence® and Bomyntra® (denosumab-bnht)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives Two Major Awards for Supply and Service Excellence from Vizient®
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and AABB Announce 20th Anniversary of Blood Collectors Week, September 7–14, 2025, Honoring Lifesaving Blood Collection Professionals
From Fresenius Kabi
Via Business Wire
Fresenius Leads New EASYGEN Consortium Aimed at Decentralizing CAR-T Cell Therapy and Improving Hospital Workflows
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives 2025 Premier Supplier Legacy Award
From Fresenius Kabi
Via Business Wire
Fresenius Expands Biosimilars Portfolio With The Launch of Denosumab Biosimilars in the U.S.
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces Epinephrine Injection, USP, in 30 mg per 30 mL Multi-Dose Vials
From Fresenius Kabi
Via Business Wire
FDA Grants Interchangeable Designation to Fresenius Kabi’s biosimilar Otulfi® (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code for Otulfi® (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Global Settlement Agreement
From Fresenius Kabi
Via Business Wire
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces Calcitonin Salmon Injection, USP Synthetic
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives FDA 510(k) Clearance for Adaptive Nomogram, Enhancing Plasma Collection Efficiency with the Aurora Xi Plasmapheresis System
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Submits 510(k) Notification for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives 2024 Novaplus Program Excellence Award from Vizient
From Fresenius Kabi
Via Business Wire
CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code and Pass-Through Payment Status for Tyenne® (tocilizumab-aazg)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Inducts 12 into National Blood Donation Hall of Fame
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and AABB Announce Start of 19th Annual Blood Collectors Week September 1-7, 2024
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Expands Women’s Health Portfolio with New Generic Option for Reproductive Health
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. for Supply Chain Innovation
From Fresenius Kabi
Via Business Wire
Arunesh Verma Joins Fresenius Kabi USA as President
From Fresenius Kabi
Via Business Wire
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
From Fresenius Kabi
Via Business Wire
Angels for Change 2024 Drug Shortage Guardian Award Presented to Fresenius Kabi USA
From Fresenius Kabi
Via Business Wire
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections
From Fresenius Kabi
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.